FHTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Foghorn Therapeutics Inc (FHTX) is not a strong buy for a beginner investor with a long-term focus at this time. The stock lacks clear positive catalysts, has no significant trading signals, and is currently in a neutral technical position. While the company has shown strong revenue growth, its financials remain negative, and there are no immediate drivers for significant price appreciation. Given the investor's profile and the absence of strong buy signals, holding off on this investment is advisable.
The technical indicators for FHTX are neutral. The MACD histogram is below 0 and negatively contracting, suggesting weak momentum. RSI is at 40.281, which is neutral and does not indicate overbought or oversold conditions. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 4.777), but there is no strong indication of a reversal or breakout.
The company's revenue increased significantly by 223.77% YoY in Q4 2025, and its gross margin remains at 100%. Additionally, the company has a clinical asset partnered with Eli Lilly, with potential mid-2026 catalysts.
The company is still operating at a net loss (-$21.66M in Q4 2025), and its EPS remains negative (-0.34). There are no significant trading trends among hedge funds or insiders, and no recent news or congress trading data to suggest immediate positive sentiment. Analyst expectations for mid-2026 indicate high uncertainty, with potential for significant downside.
In Q4 2025, Foghorn Therapeutics reported a revenue increase of 223.77% YoY to $9.25M. However, the company remains unprofitable, with a net loss of $21.66M (an 11.08% improvement YoY). EPS improved to -0.34 (up 9.68% YoY), and gross margin stayed at 100%.
Jefferies recently lowered the price target for FHTX from $14 to $12 while maintaining a Buy rating. The analyst highlighted the potential for significant price movement (80% upside or 40% downside) based on mid-2026 clinical data for FHD-909, the company's lead clinical asset.
